Mary Tagliaferri
Independent DirectorDr. Mary Tagliaferri, M.D., L.Ac., serves as an Independent Director at ADARx Pharmaceuticals, Inc. since November 2025. She is Independent Director of Iambic Therapeutics, Inc. since August 2024. Dr. Tagliaferri was Independent Director of Enzo Biochem, Inc. until August 6, 2024. Dr. Tagliaferri was Independent Chair of the Board of Enzo Biochem, Inc. from January 2022 to October 25, 2023. Dr. Tagliaferri was Independent Director of Y-mAbs Therapeutics, Inc since February 29, 2024 until July 11, 2025. Dr. Tagliaferri was Lead Independent Chairwoman of Enzo Biochem, Inc. from January 2022 to January 2022. Dr. Tagliaferri was Lead Independent Director of Enzo Biochem, Inc. from January 03, 2022. Dr. Tagliaferri was Independent Director of Enzo Biochem, Inc. from November 17, 2020 to January 03, 2022. She served as an Independent Director of RayzeBio, Inc. from September 29, 2021 until February 26, 2024. She serves as Chief Medical Officer at Nektar Therapeutics from September 2025 and served as it's Chief Medical Officer since April 2023 until February 04, 2025 and also served as Chief Development Officer since 2022 until April 2023. She served as Senior Vice President and Executive Clinical Fellow Chief Development at Nektar Therapeutics since 2020 until 2022. Dr. Tagliaferri had been Chief Medical Officer at Nektar Therapeutics since November 22, 2017 until 2020. She served as Senior Vice President of Clinical Development at Nektar Therapeutics. Dr. Tagliaferri served as Vice President of Clinical Development at Nektar Therapeutics since November 13, 2015. Dr. Tagliaferri has strategic and operational leadership at Nektar for clinical development, drug safety and risk management, as well as medical affairs and scientific writing. She has much expertise in pharmaceutical drug development and extensive regulatory expertise in oncology and women's health. Prior to joining Nektar Therapeutics in January 2015, she served as Chief Medical Officer and Chief Regulatory Officer at KangLaiTe USA. She served as Consultant to InterMune, Inc. (acquired by Roche). She co-founded Bionovo, Inc. and served as its President and Chief Medical Officer since May 2007. She has been lead author or contributor to journal publications. At BioNovo, she was responsible for all aspects of its clinical drug development strategy including spearHeading clinical studies for all drug products, overseeing global regulatory affairs, leading data management and biostatistics and ensuring the proper conduct of clinical studies. She served as the Chief Regulatory Officer, Treasurer and Secretary of Bionovo, Inc. since April 2005 and serves as its Medical Director. Dr. Tagliaferri served as Vice President of Bionovo, Inc. since April 2005. She has been a Director of Bionovo, Inc. since May 2005 and serves as its Member of Medical Advisory Board. She conducted translational research at the University of California, San Francisco from 1996 to 2002. She has spearHeaded multiple scientific R&D projects to develop pharmaceutical agents for indications in women's health and cancer. She has successfully filed a number of Investigational New Drug Licenses (INDs). She is involved in all aspects of drug development, from preclinical testing to developing FDA approved protocols for clinical trials. Dr. Tagliaferri holds an M.D. degree from University of California, San Francisco and a B.S. degree in Agricultural Economics and Business Management from Cornell University. She also hold an M.S. degree in Traditional Chinese Medicine from the American College of Traditional Chinese Medicine.
公司职务
- 公司名称Iambic Therapeutics, Inc.股票代码IAM职务Independent Director共事同僚
- TMThomas MillerCo-Founder, CEO, Secretary & Director
- WHWilliam H. RastetterIndependent Chairperson
- FRFrederick R. ManbyCo-Founder, CTO & Director
- MSMichael SecoraChief Corporate Development Officer & CFO
- PAPeter A. OlsonChief Scientific Officer
- SCSunny ChangGeneral Counsel
- SSShalini SharpIndependent Director
